Skip to main content
. 2014 Nov 1;6(6):1631–1637. doi: 10.4161/mabs.36107

Figure 2.

Figure 2.

Changes in plasma radioactivity levels (Mean ± SD, n = 3) following IV administration of [125I]- and [111In]-labeled anti-DLL4 either as tracer alone or with 2 mg/kg and 20 mg/kg of unlabeled anti-DLL4 in athymic nude mice. (A) Radioactivity of [125I] anti-DLL4; (B) Radioactivity of [111In] anti-DLL4.